Clinical Trials For My Patients - Bladder Cancer VL

Urologic Oncology Clinical Trials: Size, Scope, and Impact - Kristian Stensland

Details
Ruchika Talwar interviews Kristian Stensland about his publication in Urology Practice on the size and scope of urologic oncology clinical trials. Dr. Stensland discusses their analysis of trials registered on clinicaltrials.gov since 2007, revealing that over 100 patients enroll daily in urologic oncology trials, totaling about 28,000 participants annually. Despite this significant number, enroll...

The Best of ASCO 2024 in Advanced Bladder Cancer - Shilpa Gupta

Details
Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial's analysis of complete responders to Nivolumab plus gemcitabine-cisplatin in lymph node-only metastatic urothelial cancer; patient-reported outcomes from the EV-302 trial comparing enfortumab vedotin plus pembrolizumab to platinum chemotherapy; a...

Immunotherapy Advancements in Bladder Cancer: Clinical Trials, Early Intervention, and Toxicity Management - Matt Galsky & Neal Shore

Details
Ashish Kamat hosts a discussion with Matt Galsky and Neal Shore on the latest advancements in bladder cancer treatment, focusing on immunotherapy for advanced bladder cancer and the associated survival benefits. He emphasizes the importance of recognizing and managing immune-related toxicities. Dr. Shore discusses the application of immunotherapy in earlier stages of disease, mentioning pembrolizu...

Understanding BCG Unresponsive NMIBC: Patient Perspectives, Treatment Options, and Clinical Guidance - Gautam Jayram

Details
Ashish Kamat is joined by Gautam Jayram to unravel the complexities of BCG unresponsiveness in bladder cancer treatment. Dr. Jayram emphasizes the importance of understanding what constitutes adequate BCG treatment, highlighting the necessity of more than just six initial doses for accurate classification of BCG unresponsiveness. He sheds light on the challenges and disparities in BCG access, part...

Understanding Risk Stratification in Non-Muscle Invasive Bladder Cancer: Applying AUA Guidelines in Clinical Practice - Neal Shore

Details
Ashish Kamat is joined by Neal Shore to delve into risk stratification in non-muscle invasive bladder cancer (NMIBC). Dr. Shore highlights the crucial role of the AUA guidelines, developed with significant contributions from Dr. Kamat and others, in differentiating patients into low, intermediate, and high-risk categories. This stratification informs the frequency of cystoscopies, the intensity of...

The Southern California Research Forum: Advancing GU Cancer Care - Monty Pal & Rana McKay

Details
Rana McKay and Sumanta (Monty) Pal join Zach Klaassen in discussing the Southern California Genitourinary (GU) Cancer Research Forum, a program aimed at uniting healthcare professionals in Southern California to coordinate research and patient care in GU cancers. The program highlights include discussions on kidney cancer, bladder cancer, and prostate cancer, integrating patient advocates and show...

Consensus Recommendations to Optimize Low and Intermediate-Risk Bladder Cancer Studies, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss the Society for Immunotherapy of Cancer and the International Bladder Cancer Group's recommendations for clinical trials in bladder cancer. They focus on low and intermediate-risk non-muscle invasive bladder cancer, emphasizing the need for well-designed trials to advance treatment. The panel, comprising 25 multidisciplinary experts, aims to guide late-phase...

International Panel Defines Endpoints and Control Arms for Trials in Locally Advanced and Metastatic Bladder Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group on clinical trial designs for bladder cancer. They focus on locally advanced and metastatic urothelial carcinoma, emphasizing the need for new treatments and rational trial designs. The panel, comprising 25 multidisciplinary experts, aims to guide late-pha...

Leaders Establish Consensus Criteria for High-Risk Bladder Cancer Trials, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss the Society for Immunotherapy of Cancer and the International Bladder Cancer Group's recommendations for clinical trial design in high-risk non-muscle-invasive bladder cancer. The consensus statement, led by Dr. Ashish Kamat and published in the Journal of Clinical Oncology, aims to guide investigators in late-phase clinical trial design. The panel, comprisi...

Multi-Disciplinary Panel Defines Clinical Trial Framework for Muscle-Invasive Bladder Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group for muscle-invasive bladder cancer (MIBC) clinical trial design. Published in the Journal of Clinical Oncology with Dr. Ashish Kamat as lead author, these guidelines aim to advance treatment for urothelial carcinoma. The 25-member panel, including a patien...